Is Alzheimer's disease an apolipoprotein E amyloidosis?

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268

Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease

Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363

Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments

Ma, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871

Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid

Wisniewski, T., & Frangione, B. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90444-c · Cited by 802

Peptide Compositions of the Cerebrovascular and Senile Plaque Core Amyloid Deposits of Alzheimer′s Disease

Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin, Y. Y., Biemann, K., & Iqbal, K. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1112 · Cited by 510

Apolipoprotein E4 allele in a population–based study of early–onset Alzheimer's disease

van Duijn, C. M., de Knijff, P., Cruts, M., Wehnert, A., Havekes, L. M., Albert Hofman, D., & Broeckhoven, C. V. (1994) · Nature Genetics · doi:10.1038/ng0594-74 · Cited by 457

Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.

(1994) · PubMed Central · Cited by 441

ApoE genotype accounts for the vast majority of AD risk and AD pathology

Raber, J., Huang, Y., & Ashford, J. W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.023 · Cited by 599

Apolipoprotein E structure: insights into function

Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.008 · Cited by 583

Statins for the prevention of dementia

McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490

Cerebral Amyloid Angiopathy: A Systematic Review

Biffi, A., & Greenberg, S. M. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.1.1 · Cited by 459

Amyloid-β peptide–Receptor for Advanced Glycation Endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease

Yan, S. D., Zhu, H., Fu, J., Yan, S. F., Roher, A. E., Tourtellotte, W. W., Rajavashisth, T. B., Chen, X., Godman, G. C., Stern, D. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5296 · Cited by 429

Apolipoprotein e sets the stage: response to injury triggers neuropathology

Mahley, R. W., & Huang, Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.11.020 · Cited by 412

Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease

Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349

Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β

Koffie, R. M., Hashimoto, T., Tai, H.-C., Kay, K. R., Serrano-Pozo, A., Joyner, D., Hou, S., Kopeikina, K. J., Frosch, M. P., Lee, V. M., et al. (2012) · Brain · doi:10.1093/brain/aws127 · Cited by 327

Apolipoprotein E: From lipid transport to neurobiology

Hauser, P. S., Narayanaswami, V., & Ryan, R. O. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.09.001 · Cited by 320

Human Apolipoprotein E4 Alters the Amyloid-β 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model

Fryer, J. D., Simmons, K., Parsadanian, M., Bales, K. R., Paul, S. M., Sullivan, P. M., & Holtzman, D. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5170-04.2005 · Cited by 278

Macromolecular Crowding Accelerates Amyloid Formation by Human Apolipoprotein C-II

Hatters, D. M., Minton, A. P., & Howlett, G. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110429200 · Cited by 282

Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β peptides

TOKUDA, T., CALERO, M., MATSUBARA, E., VIDAL, R., KUMAR, A., PERMANNE, B., ZLOKOVIC, B., SMITH, J. D., LADU, M. J., ROSTAGNO, A., et al. (2000) · Biochemical Journal · doi:10.1042/bj3480359 · Cited by 272

Statins for the treatment of dementia

McGuinness, B., Craig, D., Bullock, R. A., Malouf, R. S., & Passmore, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007514.pub3 · Cited by 236

Oxidative Stress and Neurodegenerative Disorders

Sun, A. Y., & Chen, Y. (1998) · Journal of Biomedical Science · doi:10.1007/bf02255928 · Cited by 214

Statins for the prevention of dementia

McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub2 · Cited by 193

Amyloidosis and Alzheimer’s disease

Ghiso, J. A., & Frangione, B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00149-7 · Cited by 191

Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain

Näslund, J., Thyberg, J., Tjernberg, L. O., Wernstedt, C., Karlström, A. R., Bogdanović, N., Gandy, S., Lannfelt, L., Terenius, L. Y., & Nordstedt, C. (1995) · Neuron · doi:10.1016/0896-6273(95)90079-9 · Cited by 197

Biology of Aβ Amyloid in Alzheimer's Disease

Wisniewski, T., Ghiso, J., & Frangione, B. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0147 · Cited by 134

Mechanism of Cerebral β-Amyloid Angiopathy: Murine and Cellular Models

Herzig, M. C., Nostrand, W. E. V., & Jucker, M. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2006.tb00560.x · Cited by 172

Apolipoprotein E and cholesterol in aging and disease in the brain

de Chaves, E. P., Narayanaswami, V., Christoffersen, C., & Nielsen, L. B. (2008) · Future Lipidology · doi:10.2217/17460875.3.5.505 · Cited by 164

Apolipoprotein E Markedly Facilitates Age-Dependent Cerebral Amyloid Angiopathy and Spontaneous Hemorrhage in Amyloid Precursor Protein Transgenic Mice

Fryer, J. D., Taylor, J. W., DeMattos, R. B., Bales, K. R., Paul, S. M., Parsadanian, M., & Holtzman, D. M. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-21-07889.2003 · Cited by 160

Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure

Zhong, N., & Weisgraber, K. H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r800009200 · Cited by 159

Genetic Modification of the Phenotypes Produced by Amyloid Precursor Protein Overexpression in Transgenic Mice

Carlson, G. A., Borchelt, D. R., Dake, A., Turner, S., Danielson, V., Coffin, J. D., Eckman, C., Meiners, J., Nilsen, S. P., Younkin, S. G., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1951 · Cited by 158

Amyloid-β immunisation for Alzheimer's disease

Wisniewski, T., & Konietzko, U. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70170-4 · Cited by 155

A Synthetic Peptide Blocking the Apolipoprotein E/β-Amyloid Binding Mitigates β-Amyloid Toxicity and Fibril Formation in Vitro and Reduces β-Amyloid Plaques in Transgenic Mice

Sadowski, M., Pankiewicz, J., Scholtzova, H., Ripellino, J. A., Li, Y., Schmidt, S. D., Mathews, P. M., Fryer, J. D., Holtzman, D. M., Sigurdsson, E. M., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63355-x · Cited by 154

ole of apoE/Aβ Interactions in the Pathogenesis of Alzheimer's Disease and Cerebral Amyloid Angiopathy

Holtzman, D. M. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:147 · Cited by 143

Fibrillar Amyloid Protein Present in Atheroma Activates CD36 Signal Transduction

Medeiros, L. A., Khan, T., Khoury, J. B. E., Pham, C. L. L., Hatters, D. M., Howlett, G. J., Lopez, R., O’Brien, K. D., & Moore, K. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311735200 · Cited by 140

The Interaction between Apolipoprotein E and Alzheimer's Amyloid β-Peptide Is Dependent on β-Peptide Conformation

Golabek, A. A., Soto, C. A., Vogel, T., & Wısnıewskı, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.18.10602 · Cited by 137

The “Nonamyloidogenic” p3 Fragment (Amyloid β17-42) Is a Major Constituent of Down's Syndrome Cerebellar Preamyloid

Lalowski, M. M., Golabek, A. A., Lemere, C. A., Selkoe, D. J., Wı́sniewski, H. M., Beavis, R. C., Frangione, B., & Wısnıewskı, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33623 · Cited by 134

APOE-amyloid interaction: Therapeutic targets

Wisniewski, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 131

Hypercholesterolaemia and vascular dementia

Appleton, J. P., Scutt, P., Sprigg, N., & Bath, P. M. (2017) · Clinical Science · doi:10.1042/cs20160382 · Cited by 129

The Early Events That Initiate β-Amyloid Aggregation in Alzheimer’s Disease

Zhang, X., Fu, Z., Meng, L., He, M., & Zhang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00359 · Cited by 126

Apolipoprotein E epsilon 4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence

Jelić, V., Julin, P., Shigeta, M., Nordberg, A. K., Lannfelt, L., Winblad, B. G., & Wahlund, L. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.63.1.59 · Cited by 121

The classification of amyloid deposits in clinicopathological practice

Röcken, C., SCHWOTZER, E. B., Linke, R., & Saeger, W. (1996) · Histopathology · doi:10.1111/j.1365-2559.1996.tb01416.x · Cited by 115

Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis.

Wısnıewskı, T., Golabek, A. A., Kida, E., Wisniewski, K. E., & Frangione, B. (1995) · Europe PMC (PubMed Central) · Cited by 107

Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils

Hatters, D. M., Zhong, N., Rutenber, E., & Weisgraber, K. H. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.06.080 · Cited by 105

Quantitation of apoE Domains in Alzheimer Disease Brain Suggests a Role for apoE in Aß Aggregation

Cho, H. S., Hyman, B. T., Greenberg, S. M., & Rebeck, G. W. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.4.342 · Cited by 103

Electroencephalogram and Alzheimer’s Disease: Clinical and Research Approaches

Tsolaki, A., Kazis, D. A., Kompatsiaris, I. Y., Kosmidou, V. E., & Tsolaki, M. (2014) · International Journal of Alzheimer s Disease · doi:10.1155/2014/349249 · Cited by 109

The Molecular Chaperone, α-Crystallin, Inhibits Amyloid Formation by Apolipoprotein C-II

Hatters, D. M., Lindner, R. A., Carver, J. A., & Howlett, G. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105285200 · Cited by 100

Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid

Golabek, A., Marques, M. A., Lalowski, M., & Wisniewski, T. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11565-7 · Cited by 99

Annexin 5 and apolipoprotein E2 protect against Alzheimer’s amyloid-β-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site

Lee, G., Pollard, H. B., & Arispe, N. J. (2002) · Peptides · doi:10.1016/s0196-9781(02)00060-8 · Cited by 93

Association of human, rat, and rabbit apolipoprotein E with ?-amyloid

LaDu, M. J., Lukens, J. R., Reardon, C. A., & Getz, G. S. (1997) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19970701)49:1 · Cited by 92

Statins for the treatment of dementia

McGuinness, B., O’Hare, J., Craig, D., Bullock, R. A., Malouf, R. S., & Passmore, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007514.pub2 · Cited by 93

Vascular abnormalities: the insidious pathogenesis of Alzheimer’s disease☆

Shi, J., Perry, G. L., Smith, M. A., & Friedland, R. P. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00119-6 · Cited by 89

Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brain

Jones, P. B., Adams, K. W., Rozkalne, A., Spires-Jones, T. L., Hshieh, T. T., Hashimoto, T., von Armin, C. A. F., Mielke, M., Bacskai, B. J., & Hyman, B. T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014586 · Cited by 84

Isolation of Cytochrome P450 Inhibitors from Strawberry Fruit, Fragaria ananassa

Tsukamoto, S., Tomise, K., Aburatani, M., Onuki, H., Hirorta, H., Ishiharajima, E., & Ohta, T. (2004) · Journal of Natural Products · doi:10.1021/np0400104 · Cited by 84

Amyloid β40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice

Ji, Y., Permanne, B., Sigurdsson, E. M., Holtzman, D. M., & Wısnıewskı, T. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3105 · Cited by 86

Amyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural Insights

Das, M., & Gursky, O. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-17344-3_8 · Cited by 80

Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade

Potter, H., & Wısnıewskı, T. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/489428 · Cited by 84

Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain

Kida, E., Choi-Miura, N.-H., & Wisniewski, K. E. (1995) · Brain Research · doi:10.1016/0006-8993(95)00482-6 · Cited by 79

Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations

Youmans, K. L., Leung, S., Zhang, J., Maus, E., Baysac, K., Bu, G., Vassar, R., Yu, C., & LaDu, M. J. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.12.025 · Cited by 62

Glycation and Microglial Reaction in Lesions of Alzheimer's Disease

Dickson, D. W., Sinicropi, S., Yen, S.-H. C., Ko, L., Mattiace, L. A., Bucala, R., & Vlassara, H. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00116-9 · Cited by 76

Cerebral Amyloid Angiopathy: A Common Cause of Cerebral Hemorrhage

Pezzini, A., Zotto, E. D., Volonghi, I., Giossi, A., Costa, P., & Padovani, A. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788682047 · Cited by 77

Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E.

Zhou, Z., Smith, J. D., Greengard, P., & Gandy, S. (1996) · PubMed Central · Cited by 71

Can Statins Prevent or Help Treat Alzheimer's Disease?

McGuinness, B., & Passmore, P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091570 · Cited by 67

Amyloid β 1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs

Wısnıewskı, T., Lalowski, M. M., Bobik, M., RUSSELL, M., Strosznajder, J. B., & Frangione, B. (1996) · Biochemical Journal · doi:10.1042/bj3130575 · Cited by 66

The Interaction of Amyloid-β with ApoE

Carter, D. B. (2005) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/0-387-23226-5_13 · Cited by 68

Cochrane review on ‘Statins for the treatment of dementia’

McGuinness, B., O’Hare, J., Craig, D., Bullock, R. A., Malouf, R. S., & Passmore, P. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3797 · Cited by 64

Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease

Merched, A. J., Blain, H., Visvikis‐Siest, S., Herbeth, B., Jeandel, C., & Siest, G. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00234-1 · Cited by 62

Interaction of Transthyretin with Amyloid β‐Protein: Binding and Inhibition of Amyloid Formation

Schwarzman, A. L., & Goldgaber, D. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514924.ch10 · Cited by 61

Apolipoproteins and amyloid fibril formation in atherosclerosis

Teoh, C. L., Griffin, M. D. W., & Howlett, G. J. (2011) · Protein & Cell · doi:10.1007/s13238-011-1013-6 · Cited by 61

Diffuse beta-amyloid plaques and hyperphosphorylated tau are unrelated processes in aged dogs with behavioral deficits

Pugliese, M., Mascort, J., Mahy, N., & Ferrer, I. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0087-3 · Cited by 60

Detection of Apolipoprotein E/Dimeric Soluble Amyloid β Complexes in Alzheimer's Disease Brain Supernatants

Permanne, B., Perez, C., Soto, C., Frangione, B., & Wisniewski, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7727 · Cited by 49

Association between Alzheimer's Disease and a Functional Polymorphism in the Myeloperoxidase Gene

Crawford, F., Freeman, M. J., Schinka, J. A., Morris, M. D., Abdullah, L. I., Richards, D., Sevush, S., Duara, R., & MULLAN, M. J. (2001) · Experimental Neurology · doi:10.1006/exnr.2000.7560 · Cited by 59

Apolipoprotein E Carboxyl-terminal Fragments Are Complexed to Amyloids A and L

Castaño, E. M., Prelli, F., Pras, M., & Frangione, B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.29.17610 · Cited by 59

Isoform-specific proteolysis of apolipoprotein-E in the brain

Elliott, D. A., Tsoi, K., Holinkova, S., Chan, S. L., Kim, W. S., Halliday, G. M., Rye, K., & Garner, B. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.006 · Cited by 59

Suppression of apolipoprotein C‐II amyloid formation by the extracellular chaperone, clusterin

Hatters, D. M., Wilson, M. R., Easterbrook‐Smith, S. B., & Howlett, G. J. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.02957.x · Cited by 58

Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice

Pankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 57

Apolipoprotein E associated with reconstituted high‐density lipoprotein‐like particles is protected from aggregation

Hubin, E., Verghese, P. B., van Nuland, N., & Broersen, K. (2019) · FEBS Letters · doi:10.1002/1873-3468.13428 · Cited by 73

Targeting Apolipoprotein E/Amyloid β Binding by Peptoid CPO_Aβ17-21 P Ameliorates Alzheimer’s Disease Related Pathology and Cognitive Decline

Liu, S., Park, S.-A., Allington, G., Prelli, F., Sun, Y., Martá-Ariza, M., Scholtzova, H., Biswas, G. K., Brown, B., Verghese, P. B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08604-8 · Cited by 58

The human trisomy 21 brain: Insights from mouse models of Down syndrome

Holtzman, D. M., Epstein, C. J., & Mobley, W. C. (1996) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/(sici)1098-2779(1996)2:2 · Cited by 7

Immunological and Anti-Chaperone Therapeutic Approaches for Alzheimer Disease

Wısnıewskı, T., & Frangione, B. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00102.x · Cited by 54

S182 protein in Alzheimer's disease neuritic plaques

Wısnıewskı, T., Palha, J. A., Ghiso, J. A., & Frangione, B. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92379-9 · Cited by 54

ROLE OF MACROPHAGES IN ACETAMINOPHEN (PARACETAMOL)-INDUCED HEPATOTOXICITY

Goldin, R. D., Ratnayaka, I., BREACH, C. S., Brown, I. N., & Wickramasinghe, S. N. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199608)179:4 · Cited by 102

Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, Gelsolin and AA amyloids

Soto, C. A., Castaño, E. M., Prelli, F., Kumar, R., & Baumann, M. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00863-5 · Cited by 52

Apolipoprotein E is highly susceptible to oxidation by myeloperoxidase, an enzyme present in the brain

Jolivalt, C. G., Leininger‐Muller, B., Drożdż, R., Naskalski, J. W., & Siest, G. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12661-6 · Cited by 52

Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides

Forloni, G., Tagliavini, F., Bugiani, O., & Salmona, M. (1996) · Progress in Neurobiology · doi:10.1016/0301-0082(96)00013-5 · Cited by 51

Alzheimer Amyloid-β Peptide Forms Denaturant-Resistant Complex with Type ε3 but Not Type ε4 Isoform of Native Apolipoprotein E

Zhou, Z., Smith, J. D., Greengard, P., & Gandy, S. (1996) · Molecular Medicine · doi:10.1007/bf03401614 · Cited by 73

The prionoses and other conformational disorders

Wısnıewskı, T., Aucouturier, P., Soto, C. A., & Frangione, B. (1998) · Amyloid · doi:10.3109/13506129809003848 · Cited by 42

High Levels of Homocysteine Results in Cerebral Amyloid Angiopathy in Mice

Li, J.-G., & Praticò, D. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141101 · Cited by 43

Preventing β-amyloid fibrillization and deposition: β-sheet breakers and pathological chaperone inhibitors

Wısnıewskı, T., & Sadowski, M. J. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s5 · Cited by 42

The influence of Apolipoprotein E genotype on regional pathology in Alzheimer’s disease

Sabbagh, M. N., Malek‐Ahmadi, M. H., Dugger, B. N., Lee, K., Sue, L. I., Serrano, G. E., Walker, D. G., Davis, K. J., Jacobson, S. A., & Beach, T. G. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-44 · Cited by 42

Therapeutic approaches for prion and Alzheimer's diseases

Wısnıewskı, T., & Sigurdsson, E. M. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05919.x · Cited by 41

Sub‐micellar phospholipid accelerates amyloid formation by apolipoprotein C‐II

Hatters, D. M., Lawrence, L. J., & Howlett, G. J. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02355-9 · Cited by 39

Engineering Conformational Destabilization into Mouse Apolipoprotein E

Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503910200 · Cited by 38

The presence of apoE4, not the absence of apoE3, contributes to AD pathology

Teter, B., Raber, J., Nathan, B., & Crutcher, K. A. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4305 · Cited by 37

Apolipoprotein A1, the neglected relative of Apolipoprotein E and its potential role in Alzheimer’s disease

Endres, K. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.310669 · Cited by 36

Interaction between human amphipathic apolipoproteins and amyloid β‐peptide: surface plasmon resonance studies

Shuvaev, V. V., & Siest, G. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00206-2 · Cited by 36

Extracellular Proteolysis of Apolipoprotein E (apoE) by Secreted Serine Neuronal Protease

Tamboli, I. Y., Heo, D., & Rebeck, G. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093120 · Cited by 35

Apolipoprotein E deposition and astrogliosis are associated with maturation of β-amyloid plaques in βAPPswe transgenic mouse: Implications for the pathogenesis of Alzheimer’s disease

Terai, K., Iwai, A., Kawabata, S., Sasamata, M., Miyata, K., & Yamaguchi, T. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02202-8 · Cited by 36

Beta 2 microglobulin isoforms in healthy individuals and in amyloid deposits

Argilés, À., Garcia-Garcia, M., Derancourt, J., Mourad, G., & DEMAILLE, J. G. (1995) · Kidney International · doi:10.1038/ki.1995.428 · Cited by 35

Cholesterol and LDL Relate to Neuritic Plaques and to APOE4 Presence but Not to Neurofibrillary Tangles

Lesser, G. T., Beeri, M. S., Schmeidler, J., Purohit, D. P., & Haroutunian, V. (2011) · Current Alzheimer Research · doi:10.2174/156720511795563755 · Cited by 37

Transthyretin gene in Alzheimer's disease patients

Palha, J. A., Moreira, P., Wısnıewskı, T., Frangione, B., & Saraiva, M. J. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12334-x · Cited by 30

Progress Toward Identification of Protease Activity Involved in Proteolysis of Apolipoprotein E in Human Brain

Marques, M. A., Owens, P. A., & Crutcher, K. A. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:1:073 · Cited by 29

Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: a possible role for apolipoprotein E in Alzheimer's disease

Aizawa, Y., Fukatsu, R., Takamaru, Y., Tsuzuki, K., Chiba, H., Kobayashi, K., Fujii, N., & Takahata, N. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00640-9 · Cited by 29

Apolipoprotein E Is a Prime Suspect, Not Just an Accomplice, in Alzheimer's Disease

Crutcher, K. A. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:181 · Cited by 28

Apolipoprotein E in Guamanian amyotrophic lateral sclerosis/ parkinsonism-dementia complex: genotype analysis and relationships to neuropathological changes

Buée, L., Pérez‐Tur, J., Leveugle, B., Buée‐Scherrer, V., Mufson, E. J., Loerzel, A. J., Chartier‐Harlin, M., Perl, D. P., Delacourte, A., & Hof, P. R. (1996) · Acta Neuropathologica · doi:10.1007/s004010050422 · Cited by 27

Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer’s Disease

Drummond, E., Goñi, F., Liu, S., Prelli, F., Scholtzova, H., & Wısnıewskı, T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179909 · Cited by 26

A 13 kDa carboxy‐terminal fragment of ApoE stabilizes Abeta hexamers

Wellnitz, S., Friedlein, A., Bonanni, C., Anquez, V., Goepfert, F., Loetscher, H., Adessi, C., & Czech, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03295.x · Cited by 26

Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls

Hahne, S., Nordstedt, C., Åhlin, A., & Nybäck, H. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13477-2 · Cited by 25

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268

Apolipoprotein E Carboxyl-terminal Fragments Are Complexed to Amyloids A and L

Castaño, E. M., Prelli, F., Pras, M., & Frangione, B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.29.17610 · Cited by 59

Apolipoprotein E and Alzheimer's disease

Katzman, R. (1994) · Current Opinion in Neurobiology · doi:10.1016/0959-4388(94)90013-2 · Cited by 46

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.

Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525

Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.

(1994) · PubMed Central · Cited by 441